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The degree of fasthig hyperglycemia in patients with non-insulin- 
dependent diabetes mellitus is dependent on the rate of hepatic glu- 
cose production. The basal rate of hepatic glucose production is 
increased in patients with non-insulin-dependent diabetes mellitus, 
and there is a positive correlation between hepatic glucose produc- 
tion and fasting glucose levels. Diminished secretion of insulin, 
impaired hepatic sensitivity to insulin’s effects, or a combination of 
these factors could contribute to the elevated hepatic glucose pro- 
duction in patients with non-insulin-dependent diabetes mellitus. 
The relationship between insulin secretion and hepatic glucose pro- 
duction is regulated by a closed feedback loop operating between 
glucose levels and pancreatic beta cells. Although fasting insulin 
levels are usually comparable between patients with non-insulin- 
dependent diabetes mellitus and normal subjects, insulin secretion 
is markedly impaired in non-insulin-dependent diabetes mellitus in 
relation to the degree of hyperglycemia present. In fact, the degree 
of fasting hyperglycemia in a given patient with non-insulin-depend- 
ent diabetes mellitus is closely related to the degree of impaired 
pancreatic beta-cell responsiveness to glucose. Such findings sug- 
gest that impaired insulin secretion leads to increased hepatic glu- 
cose product/on, which raises the plasma glucose level. The result- 
ing hyperglycemia helps to maintain relatively normal basal insulin 
output. Chronic sulfonylurea drug therapy of patients with non-in- 
sulin-dependent diabetes mellitus enhances pancreatic islet sensi- 
tivity to glucose, leading to increased insulin secretion, suppres- 
sion of hepatic glucose production, and a decline in the steady-state 
fasting glucose level. 
The presence of hyperglycemia during the fasting state is a characteristic 
finding in patients with non-insulin-dependent diabetes mellitus and is 
currently a major diagnostic criterion for the disease [l]. The degree to 
which circulating glucose levels are elevated in the post-absorptive state 
depends on the balance between the rate of endogenous glucose pro- 
duction and the rateof removal of glucose from the circulation. Abnormal- 
ities in glucose disposal have been demonstrated in patients with non- 
insulin-dependent diabetes mellitus when circulating insulin levels are 
increased experimentally by infusion of insulin [2-51. These abnormali- 
ties may be relevant to the post-prandial hyperglycemia that also occurs 
in patients with non-insulin-dependent diabetes mellitus. However, the 
relevance of these findings to the circulating glucose levels in the fasting 
state, when insulin levels are low, is unclear. This article reviews recent 
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findings that strongly suggest that altered regulation of 
endogenous glucose production is a key feature in the 
pathogenesis of fasting hyperglycemia in type II diabetes 
mellitus. 
ROLE OF THE LIVER IN GLUCOSE HOMEOSTASIS 
After an overnight fast, the liver is the major site of glucose 
production. This glucose is derived from both breakdown 
of glycogen and gluconeogenesis, although the former 
process is more important. Among the factors determining 
the rate of hepatic glucose production is the availability of 
glycogen and of gluconeogenic precursors. The availabil- 
ity of other fuel sources may also influence glucose pro- 
duction. For example, recent evidence suggests that in- 
creased availability of free fatty acids and increased lipid 
oxidation may directly stimulate hepatic gluconeogenesis 
[6]. In the presence of an adequate amount of insulin, the 
glucose level itself can exert an inhibitory influence on 
hepatic glucose production [7]. A number of hormones 
and neural influences also contribute to the regulation of 
glucose production by the liver. Physiologically important 
short-term regulators include insulin, glucagon, and ad- 
renergic agonists. Other hormones such as glucocorti- 
coids, growth hormone, and thyroid hormone have more 
of a long-term influence on hepatic glucose production. 
Hormones secreted by the pancreatic islets drain di- 
rectly into the liver, so they are ideally suited to regulate 
hepatic glucose production. The liver is, in fact, extremely 
sensitive to changes in insulin or glucagon levels. An ex- 
ample of this sensitivity can be seen in the increased he- 
patic glucose production exhibited by normal subjects 
whose basal insulin levels were slightly suppressed dur- 
ing a two-day infusion of somatostatin with glucagon re- 
placement [8]. Although mean insulin levels only declined 
from 8 to 6 @/ml, hepatic glucose production increased 
in all subjects. This increase in hepatic glucose production 
was sufficient to cause the mean fasting glucose level to 
increase from 89 to 114 mg/dl. Thus, even a very modest 
suppression of basal insulin secretion in normal humans 
leads to increased glucose production by the liver and 
fasting hyperglycemia. 
An important feature of the interaction between pancre- 
atic islet horrnones and the liver is the closed-loop feed- 
back system illustrated in Figure 1. An increase in hepatic 
glucose production leading to increased plasma glucose 
levels will result in stimulation of insulin secretion, which 
tends to inhibit hepatic glucose production and reset 
plasma glucose levels. For example, a change in hepatic 
responsiveness to insulin will not result in significant fast- 
ing hyperglycemia due to overproduction of glucose if in- 
sulin and glucagon secretion are regulated appropriately 
by a normally functioning hepatic-pancreatic islet feed- 
back loop. It is also clear that in the presence of such a 
closed-loop feedback system, it is impossible to interpret 
one aspect of the system (e.g., plasma insulin levels) in a 
non-glucose 
stimuli 
Figure 1. Normal basal feedback loop for insulin and glu- 
cose. insulin secretion, through effects on liver, fat, and mus- 
cle, modulates the plasma glucose level by suppressing glu- 
cose production by the liver and enhancing urilization of 
glucose in fat and muscle. The blood glucose level, via inter- 
action with non-glucose stimuli, feeds back to the islet to 
maintain insulin output. (Adapted from [17] with permission.) 
meaningful way without taking into account the other reg- 
ulated variables. In particular, a comparison of circulating 
insulin levels in groups of individuals studied at different 
plasma glucose levels can lead to a gross misinterpreta- 
tion of the status of pancreatic islet function. 
ROLE OF HEPATIC GLUCOSE PRODUCTION IN THE 
FASTING HYPERGLYCEMIA OF NON-INSULIN- 
DEPENDENT DIABETES MELLITUS 
The positive correlation between fasting plasma glucose 
level and the basal rate of hepatic glucose production that 
we have observed in patients with non-insulin-dependent 
diabetes mellitus is illustrated in Figure 2 [9] and has 
been confirmed by several other recent studies [5,1 O-121. 
This positive relationship is even more impressive consid- 
ering the previously mentioned suppressive effect of hy- 
perglycemia per se on hepatic glucose production, an ef- 
fect that can also be demonstrated in patients with 
non-insulin-dependent diabetes mellitus [12]. These find- 
ings strongly suggest that increased hepatic glucose pro- 
duction contributes to the fasting hyperglycemia of pa- 
tients with type II diabetes. Further support for the 
importance of the rate of hepatic glucose production as a 
determinant of fasting plasma glucose levels in non-in- 
sulin-dependent diabetes mellitus comes from studies of 
the effects of various treatment regimens to lower these 
levels. Dietary regimens, exercise training, and sulfonylu- 
rea drug therapy, which result in lower fasting plasma glu- 
cose levels, are also associated with a reduction in glu- 
cose production by the liver [9-l 1,131. Furthermore, the 
August 23, 1985 The American Journal of Medicine Volume 79 (suppl 2B) 7 













040 60 80 100 120 
Glucose Production Rate MG/M2/MIN 
degree to which glucose production by the liver is reduced 
has been correlated with the magnitude of the decline in 
the rate of hepatic glucose production [9-l 11. 
The mechanism for the increased glucose production 
by the liver in non-insulin-dependent diabetes mellitus has 
received considerable attention. Although basal glucagon 
levels are not elevated in patients with non-insulin-de- 
pendent diabetes mellitus, glucagon responses to stimu- 
lation may be increased [14,15]. In addition, there is evi- 
dence that glucose-level suppression of glucagon 
Figure 2. Correlation between fasting 
plasma glucose level and glucose pro- 
duction rate in 20 patents with untreated 
non-insulin-dependent diabetes meliitus. 
Despite the suppressive effect of hyper- 
g/ycemia on glucose production, those 
patients with the highest glucose levels 
had the highest production rates. 
(Adapted from [9] with permission.) 
secretion is impaired in patients with non-insulin-depend- 
ent diabetes mellitus, which may contribute to abnormal 
functioning of the glucose-pancreatic islet feedback loop 
[15,16]. The recent demonstration of a positive correlation 
between free fatty acid levels, lipid oxidation rate, and 
basal hepatic glucose production in Pima Indians with 
non-insulin-dependent diabetes mellitus [5] has sug 
gested a role for increased mobilization of free fatty acids 
from fat tissue (perhaps as a result of insufficient periph- 
eral insulin availabili~} to stimulate hepatic glucose pro- 
BO- 
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Figure 3. tnsulin responses to intrave- 
nous gfuc~e s~mula~on in no~ai sub- 
jects and in patients with non-insulin- 
dependent diabetes mellitus. The aver- 
age fasting plasma glucose /eve/ for the 
normai individuals was 85 k 3 mgid!; for 
the patients with non-insulin-dependent 
diabetes mellitus, the level was 766 k 70 
mg~dl. Gfuc~e-induced ant-phase insu- 
lin secretion did not occur in patients with 
non-insulin-dependent diabetes mellitus, 
but glucose-induced second-phase. insu- 
lin secretion was preserved. (Adapted 
from [28] with permission). 
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Figure 4. Insulin response to intrave- 
nous arginine stimulation in normal sob- 
iects and in patients with non-insulin- 
dependent diabetes mellitus. The normal 
or near-normal glucose-induced second- 
phase (Figure 3) and arginine-induced 
insulin release in the diabetic subjects is 
partially maintained by their elevated 
plasma glucose levels. (Adapted from 
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duction. However, the major emphasis in studies of he- 
patic glucose production regulation in type II diabetes has 
been on the roles of impaired insulin secretion and dimin- 
ished hepatic sensitivity to insulin. 
REGULATION OF INSULIN SECRETION IN NON- 
INSULIN-DEPENDENT DIABETES MELLITUS 
Impaired pancreatic beta-cell sensitivity to glucose is 
characteristic of non-insulin-dependent diabetes mellitus 
and is an important contributing factor to the increased 
hepatic glucose production and fasting hyperglycemia in 
this disease. The acute stimulating effect of glucose on 
insulin secretion is markedly impaired in all patients with 
fasting hyperglycemia. A somewhat more subtle, but 
equally important, abnormality in beta-cell function in non- 
insulin-dependent diabetes mellitus involves the effect of 
glucose in potentiating the insulin-secretory response to a 
variety of non-glucose neural, substrate, and hormonal 
secretagogues, which contributes to the maintenance of 
both basal and post-prandial insulin levels [17]. As illus- 
trated in Figures 3 and 4, basal insulin levels and insulin 
secretory responses to non-glucose secretagogues 
measured at the basal glucose level are not below normal 
values in many patients with non-insulin-dependent dia- 
betes mellitus. However, the ability of glucose levels to 
potentiate the insulin-secretory response to non-glucose 
secretagogues is markedly impaired in these patients. 
This impairment has been demonstrated by studying the 
dose-response relationship between glucose levels and 
the insulin-secretory responses to intravenous adminis- 
tration of isoproterenol or arginine [15,18]. As shown in 
Figure 5, patients with non-insulin-dependent diabetes 
mellitus have lower insulin responses to arginine than do 
normal subjects at any matched plasma glucose level. 
Mathematical analysis of these dose-response curves has 
demonstrated a defect in islet responsiveness to maximal 
glucose levels, suggesting that an impaired beta-cell se- 
cretory capacity is characteristic of non-insulin-dependent 
diabetes mellitus [15]. 
The impairment in pancreatic beta-cell responsiveness 
to glucose can be expressed as the slope of the relation- 
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Figure 5. Comparison of acute insulin responses (mean k 
SEM) to a 5 g intravenous bolus of arginine at five plasma 
glucose levels in eight patients with non-insulin-dependent 
diabetes mellitus and eight control subjects. The insulin re- 
sponses to arginine stimulation were greater in the control 
group than in the diabetic group at all matched glucose lev- 
els (p <O.OOl at all levels). (Adapted from [15] with permis- 
sion.) 
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sponse to a non-glucose secretagogue over the linear 
portion of the dose-response curve. This value correlates 
closely with the value of the acute insulin response to the 
maximal glucose. level, the measure of beta-cell secretory 
capacity. We have found that this measure of beta-cell 
responsiveness to glucose is closely related to the fasting 
plasma glUCOS8 IeVe over a wide range of glycemia [18]. 
Thus, the most severely hyperglycemic subjects have the 
most impaired beta-cell responsiveness to glucose. 
These findings led us to postulate that basal hypergly 
cemia in non-insulin-dependent diabetes mellitus helps to 
maintain basal insulin levels and insulin responses to non- 
glucose secretagogues. This hypothesis is illustrated in 
Figure 6. We suggest that as beta-cell function declines, 
insulin levels tend to fall, and hepatic glucose production 
increases. Plasma glucose levels then rise until there is a 
sufficient potentiating effect on beta-cell function to re-es- 
tablish a new steady state in which basal insulin secretion 
is restored toward normal levels. In this way, the in- 
creased hepatic glucose production and resulting hyper- 
glycemia compensate for the impaired beta-cell function 
in non-insulin-dependent diabetes mellitus. However, 
because of the obligate loss of glucose via the kidneys as 
hyperglycemia develops, some patients with more severe 
beta-cell failure may not be able to-maintain a sufficiently 
high plasma glucose level to compensate for the degree 
of impaired beta-cell sensitivity to glucose. These patients 
havefow basal insulin levels and subnormal responses to 
both glucose and non-glucose stimuli [18]. 
non-glucose 
stimuli 
Figure 6. Schematic illustrating how hyperglycemia com- 
pensates for beta-cell dysfunction in patients with non-in- 
sulin-dependent diabetes mellitus. Insulin deficiency from an 
initial islet lesion leads to increased hepatic glucose produc- 
tion and increased hyperglycemia that, in turn, provides in- 
creased stimulation of insulin secretion. Thus, resulting basal 
insulin output is restored toward normal levels. (Adapted 
from [I 71 with permission.) 
INTERACTION OF IMPAIRED BETA-CELL FUNCTION 
AND INSULIN RESISTANCE IN NON-INSULIN- 
DEPENDENT DIABETES MELLITUS 
A number of studies have addressed the role of the de- 
creased sensitivity of the liver to insulin’s suppressive ef- 
fect on hepatic glucose production in non-insulin-depend- 
ent diabetes mellitus. Hyperinsulinemic insulin-clamp 
studies in patients with type II diabetes have demon- 
strated a shift to the right of the dose-response curve for 
suppression of hepatic glucose production by insulin, with 
total suppression of hepatic glucose production at high 
insulin levels [2,5,19]. Such a decrease in hepatic sensi- 
tivity to insulin in patients with non-insulin-dependent dia- 
betes mellitus would tend to lead to an increased rate of 
hepatic glucose production. However, because of the 
feedback loop between plasma glucose levels and beta- 
cell function, increased hepatic glucose production lead- 
ing to increased plasma glucose levels would normally 
result in increased insulin secretion, which would tend to 
overcome the hepatic insensitivity. The net result would 
be the development of hyperinsulinemia, but the mainte- 
nance of relatively normal rates of hepatic glucose pro- 
duction as well as normal levels of plasma glucose. 
Since patients with non-insulin-dependent diabetes 
mellitus have impaired beta-cell functioning, they are not 
able to compensate for the increased insulin resistance. 
Because of beta-cell insensitivity to glucose, the plasma 
glucose level may have to increase considerably in order 
to augment insulin secretion sufficiently to compensate for 
the insulin resistance. Thus, in non-insulin-dependent dia- 
betes mellitus, the plasma glucose level and the rate of 
hepatic glucose production are determined by both the 
degree of impaired beta-cell functioning and the degree of 
hepatic insensitivity to insulin. A theoretic model to predict 
the interaction of impaired beta-cell functioning and insulin 
resistance in determining the level of fasting hyperglyce- 
mia has been described [20]. However, the application of 
such a model has been limited by the lack of a validated 
approach allowing quantitative comparison of the insulin 
resistance in individual subjects. 
IMPLICATIONS FOR TREATMENT OF NON-INSULIN- 
DEPENDENT DIABETES MELLITUS 
The important contribution of increased hepatic glucose 
production to fasting plasma glucose levels in non-insulin- 
dependent diabetes mellitus and the interaction of im- 
paired beta-cell functioning and insulin resistance in the 
control of hepatic glucose production have important im- 
plications for the management of hyperglycemia in non- 
insulin-dependent diabetes mellitus. It is apparent that ef- 
forts to improve beta-cell functioning and to reduce he- 
patic unresponsiveness to insulin can both have 
therapeutic efficiency. Insulin therapy can substitute for 
the beta-cell defect and can theoretically overcome he- 
patic insulin resistance. However, large doses of insulin 
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Figure 7. Relationship between the per- 
cent change in basal insulin level and the 
change in glucose production rate in pa- 
tients with non-insulin-dependent diabe- 
tes mellitus during three to six months of 
chlorpropamide therapy. Patients who 
had the greatest relative increase in 
basal insulin level had the greatest de- 
cline in glucose production rate during 
treatment (Adapted from [9] with permis- 
sion.) 
% Change In Basal IRI 
may be needed to achieve euglycemia [21-231, both be- 
cause of the insulin resistance and because endogenous 
insulin secretion will be suppressed as plasma glucose 
levels fall as a result of the feedback loop and as a result 
of the direct suppression of beta-cell functioning by insulin 
[24-261. It is also noteworthy that insulin treatment ap- 
pears to improve the insulin resistance of patients with 
non-insulin-dependent diabetes mellitus [19, 21-231. 
Sulfonylurea drugs have been reported to improve 
beta-cell functioning and to reduce insulin resistance, al- 
though the latter effect may apply to peripheral rather than 
hepatic insulin action [27]. Long-term sulfonylurea therapy 
clearly leads to increased circulating insulin levels in many 
patients with non-insulin-dependent diabetes mellitus 
[28]. The greatest absolute increases in insulin levels are 
observed in those patients who are the most hypergly- 
cemic [29] and whose pre-treatment insulin levels were 
the lowest because of inadequately compensated beta- 
cell functioning. In fact, changes in insulin levels during 
sulfonylurea therapy are rather poor indicators of the ef- 
fect of these drugs on beta-cell function, since insulin lev- 
els reflect the negative influence of the decline of glucose 
level on beta-cells as well as the positive influence of the 
drugs. When changes in glucose levels are taken into 
account, it is clearly evident that there is a marked en- 
hancement of beta-cell sensitivity to glucose during sulfo- 
nylurea therapy in patients with non-insulin-dependent 
diabetes mellitus [29]. 
A number of studies have demonstrated that hepatic 
glucose production decreases in response to sulfonylurea 
therapy. As illustrated in Figure 7, there is a significant 
relationship between the magnitude of the fall in hepatic 
glucose production and the degree to which basal insulin 
levels increase [9]. This finding, plus the marked en- 
hancement of beta-cell sensitivity to glucose, clearly link 
the decline in hepatic glucose production and the plasma 
glucose-lowering effect of sulfonylureas to the improve- 
ment in beta-cell functioning. In contrast, because of con- 
flicting findings [9-l 11, the role of a possible improvement 
of hepatic sensitivity to insulin in the fall of hepatic glucose 
production and fasting plasma glucose during sulfonylu- 
rea therapy remains to be determined. 
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